MedBulletinsAura Celeste
Pediatrics

Monthly pediatrics bulletin — September 28, 2026

🎧 Listen to this issueAudio newscast · 6:27 min

Period covered: August 29 to September 28, 2026. A month marked by major regulatory approvals in rare diseases and pediatric nephrology, the American Academy of Pediatrics 2026-2027 immunization guidance, and surveillance data (neonatal mortality in Africa and Asia, adolescent vaccination in the United States, Dominican epidemiology). In neonatology there was no new verifiable randomized trial in the past four weeks (recent papers on dexamethasone eye drops for retinopathy, vitamin K and nirsevimab in France date from July and August), so that section relies on surveillance data. This month's items from outside North America and Western Europe come from sub-Saharan Africa and Bangladesh, the Dominican Republic, and one multinational trial. Fifteen verified items.

Neonatology

1. Eight in ten deaths among stillbirths, neonates and children under 5 in seven high-mortality countries were preventable (CHAMPS network)

[Publication] [Sub-Saharan Africa and Bangladesh]
On September 10 the CDC published in MMWR Surveillance Summaries the eight-year summary (2016-2024) of the CHAMPS network in Bangladesh, Ethiopia, Kenya, Mali, Mozambique, Sierra Leone and South Africa: of 18,784 eligible deaths, 8,500 were fully investigated with minimally invasive tissue sampling, laboratory testing and verbal autopsy. Among 3,230 neonatal deaths, complications of prematurity (about 40%), perinatal asphyxia (38%) and sepsis (37%) were the leading causes, with 44% of cases having two or more causes; among 3,199 stillbirths, perinatal asphyxia or hypoxia appeared in nearly 80%. Gram-negative bacilli accounted for about 86% of pathogen-associated neonatal deaths, with Klebsiella pneumoniae in nearly half; the expert panel judged 80.7% of the 7,558 deaths with a preventability assessment (all ages, including stillbirths) preventable or possibly preventable.
Why it matters: this is the best series of pathologically confirmed causes of neonatal death in low-income countries, but the sites are not nationally representative, facility deaths are over-captured, and "preventability" is an expert judgment. The applicable lesson is the weight of multidrug-resistant gram-negative sepsis and intrapartum asphyxia, both live problems in Dominican maternity units.
https://doi.org/10.15585/mmwr.ss7506a1

2. Dominican Republic: neonatal deaths remain 81% of infant mortality

[Epidemiological alert] [Dominican Republic]
According to epidemiological bulletin No. 36 of the Ministry of Public Health (notifications through September 12), released September 26, the country has recorded 1,349 infant deaths in 2026 versus 1,372 in the same period of 2025 (about 2% fewer); neonatal deaths fell from 1,118 to 1,100 and represent 81.5% of infant deaths. Maternal deaths fell from 126 to 101 (20% fewer; 52 Dominican, 47 Haitian).
Why it matters: the reduction is marginal and the neonatal share barely moves, which suggests that further gains will come not from vaccination or diarrhea control but from delivery care, neonatal resuscitation and management of the preterm infant and sepsis, that is, from hospital quality. These are official surveillance figures, not a study, and the bulletin itself does not break down causes.
https://listindiario.com/la-republica/sector-salud/20260926/pais-registra-50-mas-casos-dengue-ano_923706.html

Infectious diseases, vaccines and emergency care

3. AAP expands respiratory syncytial virus immunization to more high-risk children in their second season

[Guideline] [United States]
The American Academy of Pediatrics policy statement for the 2026-2027 season, published in Pediatrics on September 2, maintains immunization of all infants under 8 months born during or entering their first season (unless protected by documented maternal vaccination) and broadens the high-risk criteria for the second season (8 to 19 months): infants born before 32 weeks regardless of support needs, hemodynamically significant congenital heart disease, anatomic pulmonary abnormalities or neuromuscular disorders, Down syndrome and other chromosomal differences, in addition to the previous groups. Nirsevimab and clesrovimab are available under 8 months; only nirsevimab is indicated for the second season. According to CDC data cited by the AAP, RSV causes 50,000 to 80,000 hospitalizations per year among US children under 5.
Why it matters: the expansion is reasonable but rests on risk extrapolation, not on second-season trials in those subgroups. In the Dominican Republic none of the three products is in the public schedule; the guidance helps orient private use and advocacy before the authorities.
https://www.aap.org/en/news-room/news-releases/aap/2026/american-academy-of-pediatrics-issues-recommendations-for-rsv-immunizations-2026-2027/

4. 2026-2027 COVID-19 vaccine: AAP recommends universal dosing at 6 to 23 months and risk-based dosing at 2 to 18 years

[Guideline] [United States]
In the policy statement and technical report published the same September 2, the AAP Committee on Infectious Diseases recommends vaccinating all children aged 6 to 23 months and a single dose for those aged 2 to 18 at increased risk of severe disease, regardless of prior vaccination, offering it to any other child on parental request.
Why it matters: the AAP departs from current US federal recommendations, confirming the schism in that country's vaccine policy; the effectiveness data are observational. In the Dominican Republic the pediatric vaccine is not routinely available, so the practical impact is informational.
https://doi.org/10.1542/peds.2026-079045
https://www.aap.org/en/news-room/news-releases/aap/2026/american-academy-of-pediatrics-issues-recommendations-for-rsv-immunizations-2026-2027/

5. HPV vaccination coverage among US adolescents has stalled for four years

[Publication] [United States]
The CDC 2025 NIS-Teen report (MMWR 75(34), 18,692 adolescents aged 13 to 17) shows that 77.7% received at least one HPV vaccine dose and only 63.4% completed the series, unchanged since 2021 and far from the 80% target. Tdap and MenACWY remain near 89%, with slight declines. HPV coverage (at least one dose) is 12 points lower in mostly rural than mostly urban areas, and ranges from 49.5% (Mississippi) to 94.1% (Rhode Island) by state.
Why it matters: this is a telephone survey with a 21% response rate and provider verification in only 42%, so it may underestimate by about 5 points; even so, the plateau is real.
https://doi.org/10.15585/mmwr.mm7534a1

6. Dominican Republic: dengue up 50% and pertussis multiplies, though within the safety corridor

[Epidemiological alert] [Dominican Republic]
Epidemiological bulletin No. 36 of the Ministry of Public Health reports 338 confirmed dengue cases and one death in 2026 versus 220 cases in the same period of 2025 (50% more), with 16 cases in week 36 and the curve below the alarm threshold; the country remains among the lowest cumulative incidences in the Americas. Pertussis rose from 1 to 8 cases, meningococcal disease from 14 to 20 and non-neonatal tetanus from 14 to 19; leptospirosis nearly doubled (275 cases versus 135, 19 deaths; Puerto Plata leads with 74 cases, most during and after flooding), while malaria fell 82% (137 cases). Severe acute respiratory infections have been declining since week 27.
Why it matters: absolute numbers are low, but the rebound in pertussis and meningococcal disease calls for a review of pentavalent coverage and continued clinical suspicion in infants with paroxysmal cough; the rainy season justifies reviewing dengue warning signs with emergency staff.
https://n.com.do/2026/09/25/rd-acumula-338-casos-de-dengue-y-137-de-malaria-en-lo-que-va-del-2026/
https://listindiario.com/la-republica/sector-salud/20260926/pais-registra-50-mas-casos-dengue-ano_923706.html

General pediatrics, development, nutrition and adolescence

7. STEP Young: 40% of children aged 6 to 11 with obesity moved out of the obesity category on semaglutide

[Industry] [Denmark, multinational trial]
Novo Nordisk announced on September 7 the topline results of the phase 3 STEP Young trial: 165 children aged 6 to under 12 with obesity (more than 85% with class II or III obesity), randomized to once-weekly subcutaneous semaglutide (maximum dose 1.7 or 2.4 mg by weight) or placebo, both with a reduced-calorie diet and physical activity, for 68 weeks. The primary endpoint (percentage change in BMI) was met, but the company did not disclose the magnitude; the confirmatory secondary endpoint shows that 40.4% of treated children fell below the 95th percentile versus 0% on placebo. Safety is described as consistent with prior studies, with no signals on growth or puberty.
Why it matters: this is a manufacturer press release, without primary-endpoint or adverse-event figures, in a small trial required as a post-marketing commitment; full data will be presented at ObesityWeek (November 14-17). There is no authorization under age 12 and, in the Dominican setting, price and the lack of structured lifestyle programs are bigger barriers than the evidence.
https://www.globenewswire.com/news-release/2026/09/07/3357042/0/en/novo-nordisk-step-young-phase-3-data-40-4-of-children-living-with-obesity-achieved-a-bmi-below-the-obesity-threshold-with-semaglutide-and-lifestyle-modification.html

8. Vosoritide increases growth velocity by 2.3 cm/year in hypochondroplasia (CANOPY-HCH-3)

[Clinical trial] [United States, BioMarin]
Published in NEJM Evidence on September 9 and presented at ESPE 2026: a 52-week, placebo-controlled phase 3 trial in children with hypochondroplasia. A total of 81 participants were randomized: 41 to daily subcutaneous vosoritide and 40 to placebo. The change in annualized growth velocity was +1.95 cm/year with vosoritide versus −0.39 cm/year with placebo (difference 2.33 cm/year; 95% CI 1.85–2.82; P < 0.0001); according to BioMarin's press release, height was 2.35 cm greater and Z-score improved by 0.39. At least one adverse event occurred in 87.8% with vosoritide and 72.5% with placebo, with no grade 3 or higher events, discontinuations due to adverse events, or deaths.
Why it matters: a one-year, BioMarin-funded trial without adult height data; the manufacturer has already submitted the indication extension to the FDA (possible 2027 launch if approved). In the Dominican context the drug is neither available nor affordable, but it is worth knowing to counsel families.
https://doi.org/10.1056/EVIDoa2600257
https://www.biomarin.com/news/press-releases/biomarin-announces-positive-results-of-phase-3-voxzogo-vosoritide-study-in-hypochondroplasia-published-in-nejm-evidence/

9. Suicide-related emergency visits among US children and adolescents rose 74% from 2016 to 2022

[Publication] [United States]
A retrospective cross-sectional study from Lurie Children's Hospital of Chicago using the Nationwide Emergency Department Sample, published online in Annals of Emergency Medicine on September 3: 5,369,821 weighted visits by children aged 5 to 17 with a primary mental health diagnosis. Suicide-related visits rose from 224,850 in 2016 to 391,491 in 2022 (74% more) and all mental health visits by 24% (from 668,054 to 858,638); suicide or self-injury was the most common diagnostic group (24.1%). About half of suicide-related visits occurred at departments with fewer than 10,000 pediatric visits a year, and at the lowest-volume departments about 30% of children with mental health conditions were transferred to another hospital.
Why it matters: these are visit counts, not children, with administrative codes and no causal explanation, but the trend matches prior series. The operational message is that every emergency department, not only pediatric ones, must be ready for risk screening and safe initial care of the child or adolescent in crisis, with defined referral pathways to mental health services, something directly applicable to Dominican general hospitals.
https://doi.org/10.1016/j.annemergmed.2026.07.015
https://www.contemporarypediatrics.com/view/suicide-related-emergency-department-visits-in-us-children-rose-74-from-2016-to-2022
https://www.newswise.com/articles/children-s-suicide-related-emergency-visits-spiked-by-74-in-u-s

10. FDA approves baricitinib for severe alopecia areata in adolescents aged 12 to 17

[FDA regulatory] [United States]
Lilly announced on September 25 the expansion of baricitinib (an oral JAK inhibitor) to patients 12 and older with severe alopecia areata, based on the phase 3 BRAVE-AA-PEDS trial: in its cohort 1, 257 adolescents with SALT ≥ 50 (baseline median 100, that is, total loss) randomized to 4 mg, 2 mg or placebo. At week 36, at least 80% scalp coverage was achieved by 42% on 4 mg, 27% on 2 mg and 5% on placebo. It retains the JAK-inhibitor boxed warning (serious infections, thrombosis, malignancy) and requires tuberculosis screening and monitoring of blood counts, transaminases and lipids.
Why it matters: clear efficacy in a disease with enormous psychosocial impact, but with a safety profile that has short follow-up in adolescents; prescribing should remain with dermatology under strict monitoring.
https://investor.lilly.com/news-releases/news-release-details/fda-approves-lillys-olumiant-baricitinib-pediatric-patients-12

11. Tezepelumab meets co-primary endpoints in eosinophilic esophagitis from age 12 (CROSSING)

[Industry] [United States and United Kingdom] [Outside the period: August 27]
Amgen and AstraZeneca announced on August 27 topline results of the phase 3 CROSSING trial: 368 patients aged 12 to 80 with eosinophilic esophagitis, randomized to subcutaneous tezepelumab every 4 weeks or placebo; the anti-TSLP antibody improved esophageal histology and dysphagia scores at week 24, with effect sustained through week 52. No efficacy or adverse-event figures have been released.
Why it matters: it would be the second biologic in this disease after dupilumab, but for now it is a release without data; conference presentation and publication should precede any conclusion.
https://www.contemporarypediatrics.com/view/tezepelumab-meets-co-primary-and-secondary-endpoints-in-phase-3-eosinophilic-esophagitis-trial

Pediatric surgery and subspecialties

12. Obinutuzumab: FDA approval for childhood-onset idiopathic nephrotic syndrome

[FDA regulatory] [United States, multinational trial]
On September 25 the FDA approved obinutuzumab (anti-CD20) to reduce relapse risk in patients aged 2 and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome in complete remission. It is based on the open-label phase 3 INShore trial: 85 patients aged 2 to 25 randomized 1:1 to intravenous obinutuzumab or mycophenolate. Complete remission at week 52: 95% versus 73%, according to Genentech's statement, with fewer relapses on obinutuzumab. The label warns of hepatitis B reactivation, progressive multifocal leukoencephalopathy, infusion-related reactions and a higher risk of serious infections than with mycophenolate, and requires live vaccines at least 28 days beforehand.
Why it matters: the trial is small and open-label, and the statement does not give the week 76 result; even so, it is randomized evidence of an anti-CD20 against a standard steroid-sparing agent. Rituximab, cheaper and widely used off-label, remains the realistic option in the Dominican setting.
https://www.gene.com/media/statements/ps_092526

13. FDA approves apitegromab, first muscle-targeted therapy for spinal muscular atrophy

[FDA regulatory] [United States]
On September 11 the FDA approved apitegromab (Scholar Rock's anti-myostatin antibody) as an add-on for patients aged 2 and older with spinal muscular atrophy already receiving nusinersen or risdiplam. In the phase 3 SAPPHIRE trial (188 non-ambulatory patients aged 2 to 21; primary analysis in 156 aged 2 to 12), the 10 mg/kg intravenous dose every 4 weeks improved the Hammersmith Functional Motor Scale Expanded by 2.2 points versus placebo at one year, and 34.2% achieved a gain of 3 points or more versus 13.5% on placebo. Adverse effects: respiratory infections, vomiting, cough and increased fracture risk.
Why it matters: the functional benefit is modest but real in a population already plateaued on gene-targeted therapy; the primary analysis excluded patients over 12 and the manufacturer funded the trial. It is an additional (not replacement) treatment of very high cost, relevant mainly for the few Dominican patients who access nusinersen or risdiplam through special channels.
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-therapy-target-muscle-loss-spinal-muscular-atrophy
https://investors.scholarrock.com/news-releases/news-release-details/scholar-rock-announces-fda-approval-isembyldtm-apitegromab-mstn

14. First gene therapy for Sanfilippo syndrome type A (mucopolysaccharidosis IIIA)

[FDA regulatory] [United States]
On September 17 the FDA approved rebisufligene etisparvovec (Fayuvi, Ultragenyx), a single-dose intravenous AAV9 gene therapy delivering the SGSH gene, for children with mucopolysaccharidosis IIIA, a neurodegenerative disease with a median life expectancy of 15 years untreated. The approval rests on a single-arm open-label study in children aged 2 to 5, in which treated children maintained or improved cognitive function versus the expected decline of a historical cohort. Common adverse events: transaminase elevation, vomiting, fever, cytopenias; warning for thrombotic microangiopathy and corticosteroid prophylaxis for at least 8 weeks.
Why it matters: a milestone for families, but the evidence is a historical comparison without a concurrent control group, with uncertainty about durability and long-term oncogenic risk. It strengthens the case for expanded newborn screening, because benefit requires treating before deterioration.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-pediatric-patients-sanfilippo-syndrome-type
https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-approval-fayuvitm-gene-therapy-first-ever

15. Zilganersen, first approved treatment for Alexander disease

[FDA regulatory] [United States]
On September 3 the FDA approved zilganersen (Ionis), a quarterly intrathecal antisense oligonucleotide that reduces production of abnormal GFAP, for Alexander disease from infancy. The pivotal randomized trial (49 patients aged 2 and older per the FDA; 2:1 randomization versus control per Ionis): in patients over 5 with impaired gait, walking speed was 33.3% better than control at week 61 (P = 0.041, per Ionis); in those aged 2 to 4 gross motor function improved versus control. Under age 2, approval rests on pharmacokinetic modeling and four infants in a safety substudy. Adverse effects: vomiting, back pain, post-lumbar-puncture syndrome and cases of aseptic meningitis.
Why it matters: the first drug for an ultra-rare leukodystrophy (under 1 per million), with an effect on a functional endpoint in a tiny sample and a borderline P value; extrapolation to infants is the most fragile part. Mostly of conceptual interest: it shows intrathecal antisense drugs can modify an astrocytopathy.
https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-alexander-disease
https://ir.ionis.com/news-releases/news-release-details/zanvastrotm-zilganersen-approved-fda-first-and-only-disease

Cross-cutting

Guidelines and other items this month: IDSA updated its histoplasmosis guidance on September 16 (including when to treat pediatric pulmonary disease with itraconazole); the FDA granted Breakthrough Device Designation to an intravenous insulin dosing algorithm for hospitalized children under 2 (not yet cleared); and Abbott launched on September 7 the first ready-to-feed whole-milk infant formula in the United States (commercial announcement, no clinical data). In Brazil, the Brazilian Society of Pediatrics' resuscitation guideline for infants under 34 weeks (June 2026) remains current, with no news this month.

Upcoming meetings and dates

AAP National Conference & Exhibition, San Diego, October 2-6, 2026 (with virtual access). ObesityWeek 2026, Washington, November 14-17 (full STEP Young data). FDA decision on satralizumab for MOGAD from age 12 expected by January 10, 2027. jENS 2027 (joint European Neonatal Societies), September 21-25, 2027. The Dominican Society of Pediatrics has announced its 2027 National Congress (80th anniversary).

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.